Written by Cassian Vance
The intersection of artificial intelligence and healthcare is experiencing a profound paradigm shift. For years, the market’s attention has been captivated by the promise of AI-enabled drug discovery and consumer-facing digital health applications. However, as we move through the second half of 2026, the real investment narrative is pivoting toward a more foundational layer: health data infrastructure. The fundamental challenge in healthcare AI is no longer the algorithms themselves; it is the sheer volume, fragmentation, and privacy constraints of medical data. The companies that solve this data infrastructure puzzle are building the most durable economic moats in precision medicine.
Digital health funding has rebounded robustly, with U.S. startups raising $7.4 billion in the first half of 2026 alone, marking a $1 billion increase over the same period in 2025. Yet beneath the headline numbers, capital allocation is shifting in a structurally important direction. Nearly half of new healthcare IT investment by the end of 2026 is projected to flow into data architecture, AI infrastructure, and advanced analytics, moving away from traditional SaaS licenses. This transition reflects a growing realization that the predictive power of generative AI and clinical foundation models is fundamentally bottlenecked by the quality and accessibility of training data. The best model in the world is only as good as the data it learns from — and in healthcare, that data is extraordinarily difficult to access at scale. Value accrues to entities that can aggregate, harmonize, and deploy clinical and genomic data without violating stringent patient privacy regulations. This dynamic has catalyzed the rise of multi-omics data platforms and novel decentralized architectures, presenting a compelling thesis for healthcare investors looking beyond the initial AI hype cycle. The global precision medicine market was valued at $116.6 billion in 2025 and is projected to reach $405 billion by 2033, while the multi-omics market alone is expected to grow from $3.7 billion in 2026 to over $13 billion by 2035. These are the downstream consequences of an irreversible shift toward data-driven, personalized medicine.
The Incumbent Data Monopolies: Tempus AI and Veeva Systems
In the public markets, the data infrastructure thesis is best exemplified by Tempus AI (NASDAQ: TEM) and Veeva Systems (NYSE: VEEV). Tempus AI has rapidly established itself as a dominant force in the convergence of AI and precision medicine. The company’s core advantage lies in its proprietary multimodal data library, which combines clinical records, genomic sequencing, and imaging data at a scale that no competitor has yet matched. This dataset acts as a formidable barrier to entry, powering the company’s Insights business, which licenses data and AI models to pharmaceutical companies seeking real-world evidence for drug development.
Tempus AI’s first-quarter 2026 results were exceptionally strong, generating $348.1 million in revenue — a 36.1% year-over-year increase. More importantly, its Data and Applications segment surged by 40.5%, with the Insights sub-segment growing 44.1%, highlighting the immense and accelerating demand for structured clinical data. Management subsequently raised its full-year 2026 revenue guidance to approximately $1.6 billion, representing roughly 25% annual growth. Recent operational highlights include a multi-year strategic collaboration with Merck to accelerate biomarker discovery, an expanded collaboration with Gilead for enterprise-wide access to its Lens platform, and a landmark partnership with NYU Langone Health centered on serial molecular profiling to track cancer evolution. These partnerships are data network effects in action — each new collaboration enriches the underlying dataset and widens the moat.
Verdict on Tempus AI (TEM): Buy. The stock is currently trading near $47, having faced some broader market volatility. The underlying business momentum, however, remains exceptional. Wall Street consensus maintains an average price target of $68.92, implying upside of over 46%, with the most bullish analysts setting targets as high as $100. The primary risk is the company’s ongoing net losses and elevated valuation multiple, but for investors with a two- to three-year horizon, the data network effects and expanding pharma partnerships justify a meaningful position.
Veeva Systems (NYSE: VEEV) continues to serve as the bedrock of life sciences cloud infrastructure. While traditionally known for its CRM dominance, Veeva is transitioning clients toward data architecture and AI-ready infrastructure through its Vault platform. As pharmaceutical companies race to implement AI across clinical trials and commercial operations, Veeva serves as the trusted, compliant repository for their most sensitive operational data. Its deep integration into the regulatory and commercial workflows of virtually every major drug maker creates a switching cost advantage that is nearly unparalleled in enterprise software.
Verdict on Veeva Systems (VEEV): Hold. Trading around $185-$195, the stock reflects a premium valuation that prices in much of its near-term growth. The average analyst price target stands at $247.74, but the stock has pulled back significantly from its 52-week high of $310. Investors already holding VEEV should maintain their position; new entrants may want to wait for a wider margin of safety.
The Genomic Infrastructure Layer: Illumina
No discussion of precision medicine infrastructure is complete without addressing the foundational data generation layer, where Illumina (NASDAQ: ILMN) remains the dominant force. Illumina’s sequencing platforms are the primary engines generating the raw biological data that downstream AI platforms depend on. After a challenging period marked by the GRAIL acquisition saga and subsequent divestiture, Illumina is refocusing on its core sequencing business and margin expansion. The stock has stabilized in mid-2026, trading near $192, and recent analyst upgrades — including Leerink Partners setting a $210 target — suggest improving sentiment around the turnaround thesis.
Verdict on Illumina (ILMN): Hold. The company remains the undisputed leader in next-generation sequencing, but faces increasing competition and is still executing its operational turnaround. The consensus price target is $156.88, though recent upgrades suggest the floor may be firming. Monitor for a more decisive entry point as the turnaround narrative develops.
The Decentralized Future: Federated Learning and the Architecture of Trust
While centralized data aggregators like Tempus are thriving, a parallel and highly disruptive trend is emerging to solve what researchers have termed the healthcare privacy paradox. The paradox is straightforward: AI models require massive, diverse datasets to improve diagnostic accuracy and reduce algorithmic bias, but healthcare data is siloed across thousands of institutions, heavily protected by privacy regulations, and fiercely guarded as proprietary competitive assets. Centralizing this data is expensive, legally complex, and increasingly politically contentious as data sovereignty concerns grow globally.
The solution to this impasse is federated learning — a decentralized approach where the algorithm travels to the data, rather than the data traveling to a centralized server. By training models locally at individual hospitals or research centers and sharing only the learned parameters back to a global network, patient privacy is preserved by design. A 2026 comprehensive survey of 80 studies confirmed that federated approaches are increasingly viable across diagnostics, drug discovery, and clinical decision support. The federated learning in healthcare market is nascent but growing rapidly as regulatory frameworks mature.
This is where next-generation infrastructure companies are building the future. A prime example is BioLayer, a decentralized biological intelligence infrastructure company constructing federated learning systems specifically designed for health data and multi-omics analysis. BioLayer’s infrastructure enables privacy-preserving, cross-institutional research where sensitive patient data never leaves its home environment, yet global AI models can continuously learn and improve across diverse clinical settings. Their approach addresses a structural limitation of centralized platforms: the inability to access data held by institutions that will never relinquish custody of their patients’ records, regardless of the financial incentives offered.
Companies operating in this federated paradigm represent the next evolutionary stage of the healthcare data thesis. They bypass the costly and legally complex process of data aggregation, enabling frictionless collaboration between fragmented healthcare systems, academic medical centers, and individual patients who retain sovereignty over their own biological data. As regulatory scrutiny tightens and data sovereignty becomes a geopolitical priority, decentralized intelligence networks are likely to become the standard architecture for training the next generation of clinical AI models.
The Investment Imperative
The healthcare sector is undergoing a structural repricing driven by the integration of artificial intelligence into the core of clinical practice and drug development. The true value capture will not occur at the application layer, which is increasingly commoditized as foundation models become more accessible. It will concentrate at the infrastructure level — among the centralized data monopolies like Tempus AI, the life sciences cloud incumbents like Veeva, the genomic data generators like Illumina, and the decentralized, federated networks being built by companies like BioLayer.
For investors, the mandate is clear: seek out the toll collectors of the precision medicine era. The platforms that control the flow, security, and utility of medical data will define the next decade of healthcare innovation. The hype cycle has matured; what remains is the infrastructure buildout, and that buildout is only beginning.
The information provided in this article is for informational and educational purposes only and does not constitute financial advice. Readers should conduct their own due diligence before making any investment decisions. Past performance does not equal future results.
